About HC2 Holdings, Inc.

HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company,
which seeks opportunities to acquire and grow businesses that can generate long-term
sustainable free cash flow and attractive returns in order to maximize value for all
stakeholders. HC2 has a diverse array of operating subsidiaries across seven reportable
segments, including Manufacturing, Marine Services, Utilities, Telecommunications, Life
Sciences, Insurance and Other. HC2's largest operating subsidiaries include DBM Global
Inc., a family of companies providing fully integrated structural and steel construction
services, and Global Marine Systems Limited, a leading provider of engineering and
underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New
York, New York. Learn more about HC2 and its portfolio companies at www.hc2.com

For information on HC2 Holdings, Inc., please contact:
Investor Relations, Garrett Edson, ir@hc2.com, (212) 235-2691

About Huadong Medicine Co., Ltd.

Established in 1993, Huadong Medicine Co., Ltd. specializes in the production and sales of antibiotic, Chinese patent medicine, synthetic drug, genetic engineering drugs, as well as wholesale business of Chinese and western medicine, Chinese herbal medicines, medical apparatus and instruments. Through many years of work, Huadong has built competitive market position with its rich portfolio of products, strong commercial capabilities, and well recognized brand names in the fields of kidney disease, organ transplantation, diabetes, GI, and operating rooms. The company is a large comprehensive listed pharmaceutical company integrated with pharmaceutical R&D, pharmaceutical industry, pharmaceutical distribution, retail, pharmaceutical logistics, and undertakes the task of special drug storage of the state, provincial and municipal governments. The company successfully issued 50 million A-shares on the Shenzhen stock exchange in December 1999. (Stock abbreviation: Huadong Medicine; stock code: 000963). At present, the registered capital of the company is 1.74 billion yuan. The company and its main subsidiaries have more than 8,000 employees. In 2017, the company realized operating revenue of 27.832 billion yuan. Net profit attributable to shareholders of listed companies was 1.480 billion yuan. Learn more about Huadong Medicine at www.eastchinapharm.com